EA020523B9 - Производные хроменона с антиопухолевой активностью - Google Patents

Производные хроменона с антиопухолевой активностью

Info

Publication number
EA020523B9
EA020523B9 EA201200618A EA201200618A EA020523B9 EA 020523 B9 EA020523 B9 EA 020523B9 EA 201200618 A EA201200618 A EA 201200618A EA 201200618 A EA201200618 A EA 201200618A EA 020523 B9 EA020523 B9 EA 020523B9
Authority
EA
Eurasian Patent Office
Prior art keywords
chromenone derivatives
tumour activity
chromenone
derivatives
rhas
Prior art date
Application number
EA201200618A
Other languages
English (en)
Russian (ru)
Other versions
EA020523B1 (ru
EA201200618A1 (ru
Inventor
Бернар Кристоф Барлам
Себастьен Луи Дегорс
Кристин Мари Поль Ламбер-Ван Дер-Бремт
Реми Робер Моржентен
Патрик Пле
Original Assignee
Астразенека Аб
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Астразенека Аб filed Critical Астразенека Аб
Publication of EA201200618A1 publication Critical patent/EA201200618A1/ru
Publication of EA020523B1 publication Critical patent/EA020523B1/ru
Publication of EA020523B9 publication Critical patent/EA020523B9/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/74—Benzo[b]pyrans, hydrogenated in the carbocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/22—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
    • C07F7/1804—Compounds having Si-O-C linkages
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrane Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
EA201200618A 2009-10-27 2010-10-25 Производные хроменона с антиопухолевой активностью EA020523B9 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP09306017 2009-10-27
PCT/GB2010/051788 WO2011051704A1 (en) 2009-10-27 2010-10-25 Chromenone derivatives with anti-tumour activity

Publications (3)

Publication Number Publication Date
EA201200618A1 EA201200618A1 (ru) 2012-12-28
EA020523B1 EA020523B1 (ru) 2014-11-28
EA020523B9 true EA020523B9 (ru) 2015-01-30

Family

ID=43085922

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201200618A EA020523B9 (ru) 2009-10-27 2010-10-25 Производные хроменона с антиопухолевой активностью

Country Status (41)

Country Link
US (5) US8399460B2 (index.php)
EP (1) EP2493870B1 (index.php)
JP (2) JP5657010B2 (index.php)
KR (1) KR101738195B1 (index.php)
CN (2) CN104447657B (index.php)
AR (1) AR078786A1 (index.php)
AU (1) AU2010311107B9 (index.php)
BR (1) BR112012010124B8 (index.php)
CA (1) CA2776994C (index.php)
CL (1) CL2012001056A1 (index.php)
CO (1) CO6541528A2 (index.php)
CR (1) CR20120217A (index.php)
CU (1) CU20120069A7 (index.php)
CY (1) CY1116143T1 (index.php)
DK (1) DK2493870T3 (index.php)
DO (1) DOP2012000124A (index.php)
EA (1) EA020523B9 (index.php)
EC (1) ECSP12011838A (index.php)
ES (1) ES2530943T3 (index.php)
GT (1) GT201200126A (index.php)
HN (1) HN2012000889A (index.php)
HR (1) HRP20150146T1 (index.php)
IL (1) IL219191A0 (index.php)
IN (1) IN2012DN03328A (index.php)
ME (1) ME02050B (index.php)
MX (1) MX2012005027A (index.php)
MY (1) MY179833A (index.php)
NI (1) NI201200081A (index.php)
NZ (1) NZ599457A (index.php)
PE (1) PE20130149A1 (index.php)
PH (1) PH12012500804A1 (index.php)
PL (1) PL2493870T3 (index.php)
PT (1) PT2493870E (index.php)
RS (1) RS53813B1 (index.php)
SA (1) SA110310808B1 (index.php)
SI (1) SI2493870T1 (index.php)
SM (1) SMT201500036B (index.php)
TW (1) TWI483939B (index.php)
UA (1) UA107474C2 (index.php)
UY (1) UY32978A (index.php)
WO (1) WO2011051704A1 (index.php)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2725014C (en) 2008-05-30 2014-06-17 Amgen Inc. Inhibitors of pi3 kinase
US8399460B2 (en) * 2009-10-27 2013-03-19 Astrazeneca Ab Chromenone derivatives
US8530470B2 (en) * 2011-04-13 2013-09-10 Astrazeneca Ab Chromenone derivatives
BR112015017331B1 (pt) 2013-01-23 2022-01-11 Astrazeneca Ab Compostos de formula i, forma cristalina, uso dos compostos, combinação e composição
BR112015019524A8 (pt) * 2013-03-04 2019-11-19 Astrazeneca Ab combinação de um composto [i] com um taxano, método de produção de efeito anticancer, uso de um composto [i] em combinação com um taxano, composição farmacêutica e kit no tratamento de câncer
CA2952025A1 (en) 2014-06-13 2015-12-17 Gilead Sciences, Inc. Phosphatidylinositol 3-kinase inhibitors
WO2015191752A1 (en) 2014-06-13 2015-12-17 Gilead Sciences, Inc. Phosphatidylinositol 3-kinase inhibitors
ES2763104T3 (es) 2014-06-13 2020-05-27 Gilead Sciences Inc Derivados de quinazolinona como inhibidores de fosfatidilinositol 3-quinasa
US11021467B2 (en) 2014-06-13 2021-06-01 Gilead Sciences, Inc. Phosphatidylinositol 3-kinase inhibitors
WO2015191754A2 (en) 2014-06-13 2015-12-17 Gilead Sciences, Inc. Phosphatidylinositol 3-kinase inhibitors
CN104744376A (zh) * 2015-03-14 2015-07-01 长沙深橙生物科技有限公司 一种2-异丙基嘧啶衍生物的制备方法
CN104803921A (zh) * 2015-03-14 2015-07-29 长沙深橙生物科技有限公司 一种苯取代嘧啶衍生物的制备方法
KR101766731B1 (ko) 2015-06-23 2017-08-10 충남대학교산학협력단 강심 활성을 갖는 크로메논 유도체 및 이를 포함하는 심부전의 예방 또는 치료용 약학 조성물
BR112018007068B1 (pt) * 2015-10-09 2024-01-02 Janssen Pharmaceutica N.V. Derivados de quinoxalina e piridopirazina como inibidores de pi3kbeta, seu uso e composição farmacêutica que os compreende
WO2018057808A1 (en) 2016-09-23 2018-03-29 Gilead Sciences, Inc. Benzimidazole derivatives and their use as phosphatidylinositol 3-kinase inhibitors
TW201815787A (zh) 2016-09-23 2018-05-01 美商基利科學股份有限公司 磷脂醯肌醇3-激酶抑制劑
TW201813963A (zh) 2016-09-23 2018-04-16 美商基利科學股份有限公司 磷脂醯肌醇3-激酶抑制劑
TW201825465A (zh) 2016-09-23 2018-07-16 美商基利科學股份有限公司 磷脂醯肌醇3-激酶抑制劑
AR121719A1 (es) 2020-04-03 2022-06-29 Petra Pharma Corp Inhibidores alostéricos de cromenona del fosfoinosítido 3-quinasa (pi3k) para el tratamiento de enfermedades
KR20210141214A (ko) * 2020-05-15 2021-11-23 제이투에이치바이오텍 (주) 3원환 화합물 및 이의 의약 용도
EP4284375A4 (en) * 2021-02-01 2025-04-23 Geode Therapeutics Inc. PHOSPHOINOSITIDE 3-KINASE BETA INHIBITORS AND COMPOSITIONS AND METHODS THEREFOR
EP4333984A1 (en) 2021-05-03 2024-03-13 Petra Pharma Corporation Allosteric chromenone inhibitors of phosphoinositide 3-kinase (pi3k) for the treatment of disease
BR112023022580A2 (pt) * 2021-05-03 2024-01-09 Petra Pharma Corp Inibidores alostéricos de cromenona de fosfoinositídeo 3-quinase (pi3k) para o tratamento de doenças
JP7702057B2 (ja) * 2021-05-27 2025-07-03 ペトラ・ファーマ・コーポレイション がんの治療のためのホスホイノシチド３－キナーゼ（ｐｉ３ｋ）のアロステリッククロメノン阻害剤
TW202329930A (zh) 2021-09-30 2023-08-01 美商佩特拉製藥公司 用於治療疾病之磷酸肌醇3-激酶(pi3k)之異位色烯酮抑制劑
CA3232906A1 (en) * 2021-10-07 2023-04-13 Alessandro Boezio Pi3k-alpha inhibitors and methods of use thereof
EP4444714A4 (en) * 2021-12-08 2025-10-29 Nanjing Zenshine Pharmaceuticals Co Ltd CONDENSED HETEROCYCLIC COMPOUNDS USED AS PI3KALPHA INHIBITORS
WO2024003241A1 (en) 2022-06-30 2024-01-04 Astrazeneca Ab Treatment for immuno-oncology resistant subjects with an anti pd-l1 antibody an antisense targeted to stat3 and an inhibitor of ctla-4
WO2024081904A1 (en) * 2022-10-14 2024-04-18 Genesis Therapeutics, Inc. Methods for treating cancer
CN119431297A (zh) * 2023-08-02 2025-02-14 郑州同源康医药有限公司 稠环类化合物及其用途

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004016607A1 (en) * 2002-08-16 2004-02-26 Kinacia Pty Ltd. Inhibition of phosphoinositide 3-kinase beta

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6027A (en) * 1849-01-09 Rotary blacksmith s twyer
HUT58310A (en) 1988-12-21 1992-02-28 Upjohn Co Anti-atherosclerotic and anti-thrombotic 1-benzopyran-4-one- and 2-amino-1,3-benzoxazin-4-one derivatives, process for producing them and pharmaceutical compositions containing them
ATE158288T1 (de) 1990-06-20 1997-10-15 Upjohn Co Antiatherosklerotische und antithrombotische 1- benzopyran-4-on- und 2-amino-1,3-benzoxazin-4-on- derivate
DE4318756A1 (de) 1993-06-05 1994-12-08 Hoechst Ag Substituierte Benzoylguanidine, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament
GB9624482D0 (en) 1995-12-18 1997-01-15 Zeneca Phaema S A Chemical compounds
HUP9901155A3 (en) 1996-02-13 2003-04-28 Astrazeneca Ab Quinazoline derivatives as vegf inhibitors
ES2169355T3 (es) 1996-03-05 2002-07-01 Astrazeneca Ab Derivados de 4-anilinoquinazolina.
GB9718972D0 (en) 1996-09-25 1997-11-12 Zeneca Ltd Chemical compounds
GB9714249D0 (en) 1997-07-08 1997-09-10 Angiogene Pharm Ltd Vascular damaging agents
GB9900334D0 (en) 1999-01-07 1999-02-24 Angiogene Pharm Ltd Tricylic vascular damaging agents
GB9900752D0 (en) 1999-01-15 1999-03-03 Angiogene Pharm Ltd Benzimidazole vascular damaging agents
CN1167422C (zh) 1999-02-10 2004-09-22 阿斯特拉曾尼卡有限公司 用作血管生成抑制剂的喹唑啉衍生物
DE60128655T2 (de) 2000-01-24 2008-02-07 Astrazeneca Ab Durch einen morpholinrest substituierte therapeutische verbindungen
EP1289952A1 (en) 2000-05-31 2003-03-12 AstraZeneca AB Indole derivatives with vascular damaging activity
UA73993C2 (uk) 2000-06-06 2005-10-17 Астразенека Аб Хіназолінові похідні для лікування пухлин та фармацевтична композиція
IL153484A0 (en) 2000-07-07 2003-07-06 Angiogene Pharm Ltd Colchinol derivatives as angiogenesis inhibitors
IL153325A0 (en) 2000-07-07 2003-07-06 Angiogene Pharm Ltd Colchinol derivatives as angiogenesis inhibitors
AR054438A1 (es) * 2005-04-15 2007-06-27 Kudos Pharm Ltd Inhibidores de adn -pk
WO2007045876A1 (en) 2005-10-21 2007-04-26 Merz Pharma Gmbh & Co. Kgaa Chromenones and their use as modulators of metabotropic glutamate receptors
SI2004654T1 (sl) * 2006-04-04 2013-11-29 The Regents Of The University Of California Pirazolopirimidinski derivati za uporabo kot kinazni antagonisti
WO2008064244A2 (en) 2006-11-20 2008-05-29 The Trustees Of Columbia University In The City Of New York Phosphoinositide modulation for the treatment of neurodegenerative diseases
EP2112145A1 (en) 2008-04-24 2009-10-28 AxoGlia Therapeutics S.A. Chromenone derivatives useful for the treatment of neurodegenerative diseases
WO2010134082A1 (en) 2009-05-21 2010-11-25 Proteologics Ltd Chromenone derivatives for treatment of cancer
US8399460B2 (en) * 2009-10-27 2013-03-19 Astrazeneca Ab Chromenone derivatives

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004016607A1 (en) * 2002-08-16 2004-02-26 Kinacia Pty Ltd. Inhibition of phosphoinositide 3-kinase beta
US20060276470A1 (en) * 2002-08-16 2006-12-07 Jackson Shaun P Inhibition of phsphoinostide 3-dinase beta

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
GRIFFIN R.J. ET AL.: "Selective benzopyranone and pyrimido[2,1-a]isoquinolin-4-one inhibitors of DNA-dependent protein kinase: Synthesis, structure-activity studies, and radiosensitization of a human tumor cell line in vitro", JOURNAL OF MEDICINAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY, WASHINGTON, US, vol. 48, no. 2, 27 January 2005 (2005-01-27), pages 569-585, XP002381166, ISSN: 0022-2623, DOI:10.1021/JM049526A, Abstract; Table 2 (A) and Conclusions *

Also Published As

Publication number Publication date
PL2493870T3 (pl) 2015-04-30
CU20120069A7 (es) 2012-10-15
CN102712615B (zh) 2014-12-17
HK1174027A1 (en) 2013-05-31
CN102712615A (zh) 2012-10-03
CR20120217A (es) 2012-06-28
SMT201500036B (it) 2015-05-05
AR078786A1 (es) 2011-11-30
AU2010311107A1 (en) 2012-05-03
MY179833A (en) 2020-11-17
UY32978A (es) 2011-05-31
US20160060240A1 (en) 2016-03-03
CA2776994A1 (en) 2011-05-05
IL219191A0 (en) 2012-06-28
EP2493870B1 (en) 2014-12-17
ME02050B (me) 2015-05-20
ES2530943T3 (es) 2015-03-09
SA110310808B1 (ar) 2013-11-24
HN2012000889A (es) 2015-08-03
EA020523B1 (ru) 2014-11-28
NZ599457A (en) 2014-04-30
JP5872016B2 (ja) 2016-03-01
KR20120098724A (ko) 2012-09-05
RS53813B1 (sr) 2015-06-30
NI201200081A (es) 2012-11-07
PT2493870E (pt) 2015-02-18
CL2012001056A1 (es) 2012-10-05
EA201200618A1 (ru) 2012-12-28
GT201200126A (es) 2014-03-03
TWI483939B (zh) 2015-05-11
UA107474C2 (uk) 2015-01-12
BR112012010124B8 (pt) 2021-05-25
CA2776994C (en) 2017-10-31
US8399460B2 (en) 2013-03-19
JP2015078202A (ja) 2015-04-23
DK2493870T3 (en) 2015-02-23
DOP2012000124A (es) 2012-07-15
EP2493870A1 (en) 2012-09-05
HK1206335A1 (zh) 2016-01-08
AU2010311107B9 (en) 2014-06-19
US20110098271A1 (en) 2011-04-28
CO6541528A2 (es) 2012-10-16
IN2012DN03328A (index.php) 2015-10-23
ECSP12011838A (es) 2012-06-29
AU2010311107B2 (en) 2014-03-27
CY1116143T1 (el) 2017-02-08
BR112012010124A2 (pt) 2016-06-07
PH12012500804A1 (en) 2022-10-03
US20140194419A1 (en) 2014-07-10
KR101738195B1 (ko) 2017-05-19
SI2493870T1 (sl) 2015-03-31
CN104447657B (zh) 2016-08-17
US9718800B2 (en) 2017-08-01
JP2013508449A (ja) 2013-03-07
US20130158026A1 (en) 2013-06-20
MX2012005027A (es) 2012-09-07
PE20130149A1 (es) 2013-03-10
WO2011051704A1 (en) 2011-05-05
JP5657010B2 (ja) 2015-01-21
US9029374B2 (en) 2015-05-12
TW201121960A (en) 2011-07-01
HRP20150146T1 (hr) 2015-05-22
US8673906B2 (en) 2014-03-18
CN104447657A (zh) 2015-03-25
US20160272607A1 (en) 2016-09-22
BR112012010124B1 (pt) 2021-02-17

Similar Documents

Publication Publication Date Title
EA020523B9 (ru) Производные хроменона с антиопухолевой активностью
MX2013011931A (es) Compuestos de cromenona como inhibidores de pi 3-quinasa para el tratamiento del cancer.
MD20140086A2 (ro) Derivaţi macrociclici pentru tratamentul bolilor proliferative
MX345928B (es) Composiciones terapeuticamente activas y metodos de uso de las mismas.
MX2014000341A (es) Novedosos derivados de trifluoro-metil-oxadiazol y su uso en el tratamiento de enfermedades.
IL217378A (en) History of oxazin, containing pharmaceuticals and their use in the preparation of drugs for the treatment of neurological disorders
PH12014501542A1 (en) Substituted pyrrolidine -2- carboxamides
PH12013501600A1 (en) Novel heterocyclic derivatives
PH12013500473A1 (en) Triazine-oxadiazoles
IN2014DN09434A (index.php)
TN2014000175A1 (en) Novel purine derivatives and their use in the treatment of disease
MX2012008328A (es) Derivados de pirazina.
MY148948A (en) Catecholamine derivatives and prodrugs thereof
PH12014501514A1 (en) New azetidine derivatives, pharmaceutical compositions and uses thereof
WO2013004995A8 (en) Pyrimidinone compounds and their use
PH12013500007A1 (en) Piperidine derivatives and their use for the treatment of metabolic disorders
MX340574B (es) Imidazo pirazinas.
MY156302A (en) COMPOUNDS, COMPOSITIONS AND METHODS FOR THE TREATMENT OF ß-AMYLOID DISEASES AND SYNUCLEINOPATHIES
MX2015004362A (es) Derivados de ketamina.
TW201129560A (en) 4-[2-[[5-methyl-1-(2-naphtalenyl)-1H-pyrazol-3-yl]oxy]ethyl]morpholine salts
MX2012013879A (es) Derivados de hidroxipiridona, composiciones farmceuticas de los mismos y su uso terapeutico para tratar enfermedades proliferativas.
WO2012162439A3 (en) Compositions comprising fusidic acid and packages therefor
BR112014009580A2 (pt) composição farmacêutica de omeprazol
WO2014062838A3 (en) Pkm2 modulators and methods for their use
WO2014043252A3 (en) Hydroxypyridinone-,hydroxypyrimidinone-and hydroxypyridazinone drivatives and their therapeutic application

Legal Events

Date Code Title Description
TH4A Publication of the corrected specification to eurasian patent
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KG MD TJ TM

MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): KZ